WO2009068906A3 - Combinations comprising zd4054 and a src family kinase inhibitor 172 - Google Patents

Combinations comprising zd4054 and a src family kinase inhibitor 172 Download PDF

Info

Publication number
WO2009068906A3
WO2009068906A3 PCT/GB2008/051106 GB2008051106W WO2009068906A3 WO 2009068906 A3 WO2009068906 A3 WO 2009068906A3 GB 2008051106 W GB2008051106 W GB 2008051106W WO 2009068906 A3 WO2009068906 A3 WO 2009068906A3
Authority
WO
WIPO (PCT)
Prior art keywords
kinase inhibitor
combinations
src family
family kinase
src
Prior art date
Application number
PCT/GB2008/051106
Other languages
French (fr)
Other versions
WO2009068906A2 (en
Inventor
Daniel Mark Hickinson
Original Assignee
Astrazeneca Ab
Astrazeneca Uk Ltd
Daniel Mark Hickinson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Astrazeneca Uk Ltd, Daniel Mark Hickinson filed Critical Astrazeneca Ab
Publication of WO2009068906A2 publication Critical patent/WO2009068906A2/en
Publication of WO2009068906A3 publication Critical patent/WO2009068906A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A combination, comprising N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4- oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide, or a pharmaceutically acceptable salt thereof, and a Src kinase inhibitor is described.
PCT/GB2008/051106 2007-11-26 2008-11-24 Combinations comprising zd4054 and a src family kinase inhibitor 172 WO2009068906A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99001007P 2007-11-26 2007-11-26
US60/990,010 2007-11-26

Publications (2)

Publication Number Publication Date
WO2009068906A2 WO2009068906A2 (en) 2009-06-04
WO2009068906A3 true WO2009068906A3 (en) 2009-07-23

Family

ID=40350059

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2008/051106 WO2009068906A2 (en) 2007-11-26 2008-11-24 Combinations comprising zd4054 and a src family kinase inhibitor 172

Country Status (1)

Country Link
WO (1) WO2009068906A2 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001094341A1 (en) * 2000-06-06 2001-12-13 Astrazeneca Ab Quinazoline derivatives for the treatment of tumours
WO2004018044A2 (en) * 2002-08-23 2004-03-04 Astrazeneca Ab N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-'1,3,4-oxadiazol-2-yl!phenyl)pyridine-3 sulphonamide as an anticancer agent
WO2004041829A1 (en) * 2002-11-04 2004-05-21 Astrazeneca Ab Quinazoline derivatives as src tyrosine kinase inhibitors
WO2004098604A1 (en) * 2003-05-07 2004-11-18 Astrazeneca Ab Therapeutic agents comprising an anti-angiogenic agent in combination with an src-inhibitor and their therapeutic use
WO2006064217A2 (en) * 2004-12-17 2006-06-22 Astrazeneca Ab PROCESS FOR THE PREPARATION OF 4-(6-CHLORO-2, 3-METHYLENEDIOXYANILINO)-7-[2-(4-METHYLPIPERAZIN-l-YL) ETHOXY]-5-TETRAHYDROPYRAN-4-YLOXYQUINAZOLINE , THEIR INTERMEDIATES AND CRYSTALLINE SALTS THEREOF

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001094341A1 (en) * 2000-06-06 2001-12-13 Astrazeneca Ab Quinazoline derivatives for the treatment of tumours
WO2004018044A2 (en) * 2002-08-23 2004-03-04 Astrazeneca Ab N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-'1,3,4-oxadiazol-2-yl!phenyl)pyridine-3 sulphonamide as an anticancer agent
WO2004041829A1 (en) * 2002-11-04 2004-05-21 Astrazeneca Ab Quinazoline derivatives as src tyrosine kinase inhibitors
WO2004098604A1 (en) * 2003-05-07 2004-11-18 Astrazeneca Ab Therapeutic agents comprising an anti-angiogenic agent in combination with an src-inhibitor and their therapeutic use
WO2006064217A2 (en) * 2004-12-17 2006-06-22 Astrazeneca Ab PROCESS FOR THE PREPARATION OF 4-(6-CHLORO-2, 3-METHYLENEDIOXYANILINO)-7-[2-(4-METHYLPIPERAZIN-l-YL) ETHOXY]-5-TETRAHYDROPYRAN-4-YLOXYQUINAZOLINE , THEIR INTERMEDIATES AND CRYSTALLINE SALTS THEREOF

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HICKINSON MARK ET AL: "Enhanced in vitro anti-invasive activity in A673 rhabdomyosarcoma cells of the specific endothelin-A receptor (ETA) antagonist ZD4054 when combined with the novel Src inhibitor AZD0530", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 49, April 2008 (2008-04-01), & 99TH ANNUAL MEETING OF THE AMERICAN-ASSOCIATION-FOR-CANCER-RESEARCH; SAN DIEGO, CA, USA; APRIL 12 -16, 2008, pages 349, XP001537134, ISSN: 0197-016X *
SUMMY J M ET AL: "Treatment for advanced tumors: Src reclaims center stage", CLINICAL CANCER RESEARCH 20060301 US, vol. 12, no. 5, 1 March 2006 (2006-03-01), pages 1398 - 1401, XP008106825, ISSN: 1078-0432 *

Also Published As

Publication number Publication date
WO2009068906A2 (en) 2009-06-04

Similar Documents

Publication Publication Date Title
WO2009047565A3 (en) Zibotentan composition containing mannitol and/or microcrystalline cellulose
EP2099457A4 (en) Cytoskeletal active rho kinase inhibitor compounds, composition and use
WO2007048064A3 (en) Amino-pyrimidines as casein kinase ii (ck2) modulators
ZA200902469B (en) 4-[4-({[4-Chloro-3(Trifluoromethyl)Phenyl)]Carbamoyl} Amino)-3-Fluorophenoxy]-N-Methylpyridine-2-Carboxamide Monohydrate
WO2007096151A3 (en) Inhibitors of p38-kinase for treatment of pulmonary hypertension
RS53845B1 (en) Oxadiazole derivatives and their use as metabotropic glutamate receptor -842 potentiators
IL192298A (en) Heterocyclic compounds, pharmaceutical acceptable salts thereof, pharmaceutical compositions comprising the same and uses thereof
WO2007125310A3 (en) Pharmaceutical combinations of pk inhibitors and other active agents
WO2005110410A3 (en) Kinase inhibitors as therapeutic agents
IL200561A (en) Heterocyclic aspartyl protease inhibitors or tautomers thereof, pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising same and use thereof
WO2009016072A3 (en) A morpholinyl anthracycline derivative combined with protein kinase inhibitors
WO2008033798A3 (en) A pyrrolopyrazin as syk-kinase inhibitor
WO2007112014A3 (en) New therapeutic combinations for the treatment of depression
WO2008060476A3 (en) Nitrogen-containing heterocyclic compounds and methods of use thereof
WO2007149730A3 (en) Inhibitors of akt (protein kinase b)
HRP20080446T3 (en) Monohydrochloride salt of 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-piperidine
WO2007099171A3 (en) Bicyclo-pyrazoles active as kinase inhibitors
TW200628458A (en) Metasubstituted thiazolidinones, their manufacture and use as a drug
IL179346A0 (en) 3-(4-(2-dihydroisoxazol-3-ylpyridin-5-yl)phenyl)-5-triazol-1-ylmethyloxazolidin-2-one derivatives as mao inhibitors for the treatment of bacterial infections
WO2006048152A3 (en) Dicarboxamide derivatives and their use as factor xa inhibitors
WO2003047517A3 (en) Novel-n-[4-(1h-imidazol-1-yl)-2-fluorophenyl]-3-(trifluoromethyl)-1-h-pyrazole-5-carboxamides as factor xa
EP2007391B8 (en) Combination comprising a) a pyrimidylaminobenzamide compound, and b) a thr315ile kinase inhibitor
WO2006079923A3 (en) Form iv crystalline celecoxib
WO2006027345A3 (en) Novel 3-thia-10-aza-phenanthrene derivatives
WO2007010235A8 (en) Ethanolamine salt of n- (3-methoxy-5-methylpyrazin-2yl) -2- (4- [1 , 3 , 4-0xadiaz0le-2-yl] phenyl) pyridine-3- sulphonamide

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08853649

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08853649

Country of ref document: EP

Kind code of ref document: A2